This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This series is based on primary research data collected at one month, three months, and one year after commercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, the report assesses U.S. hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. The analysis provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other recently launched oncology drugs.

Table of contents

  • Multiple Myeloma - Emerging Therapies - Darzalex/Empliciti Launch Tracking Wave 3 (US)
    • Key Findings
      • Benchmarking Darzalex's and Empliciti's Launch Success vs. Other Launched Drugs
        • Usage Levels by Physicians Are Lower for Darzalex and Empliciti Than for Other Benchmark Drugs
      • Prescriber and Nonprescriber Profiles
        • Who Are the Darzalex and Empliciti Prescribers?
        • Darzalex Prescriber vs. Nonprescriber Profile
        • Empliciti Prescriber vs. Nonprescriber Profile
      • Darzalex and Empliciti Awareness and Perceptions
        • Unaided and Aided Awareness of Darzalex and Empliciti
          • Unaided Awareness of Select Drugs for Multiple Myeloma
          • Aided Awareness of Darzalex and Empliciti
        • Familiarity with Darzalex and Empliciti
          • Most Physicians Report High Levels of Familiarity with Darzalex and Empliciti
          • Darzalex and Empliciti Familiarity Ratings
          • Darzalex: Approved Patient Populations
          • Empliciti: Approved Patient Populations
          • Estimated Monthly Costs of Darzalex and Empliciti
          • Estimated Mean Monthly Cost of Darzalex and Empliciti
        • Sources of Familiarity with Darzalex and Empliciti
          • Information Sources Promoting Familiarity with Darzalex and Empliciti
          • Other Sources of Familiarity with Darzalex and Empliciti
        • Initial Reaction to and Interest in Darzalex and Empliciti
          • Darzalex Product Profile
          • Empliciti Product Profile
          • Physicians Indicate Moderate to High Levels of Interest in Darzalex and Empliciti
          • Initial Reactions to Darzalex and Empliciti
          • Levels of Interest in Darzalex and Empliciti
        • Impressions of Darzalex and Empliciti
          • Majority of Physicians Find Darzalex and Empliciti to Be Highly Unique Compared with Other Multiple Myeloma Agents
          • Views on the Uniqueness of Darzalex and Empliciti
          • Perceived Advantages of Darzalex and Empliciti
          • Perceived Disadvantages of Darzalex and Empliciti
          • Balance Between Risks and Benefits of Darzalex and Empliciti
          • Physician Quotes on Impressions of Darzalex
          • Physician Quotes on Impressions of Empliciti
        • Prescriber and Nonprescriber Profiles
          • Darzalex Prescriber vs. Nonprescriber Profile
          • Empliciti Prescriber vs. Nonprescriber Profile
      • Darzalex and Empliciti Trial and Use
        • Willingness to Prescribe Darzalex and Empliciti
          • Willingness to Prescribe Darzalex and Empliciti Is High
          • Willingness to Prescribe Darzalex + Rd and Darzalex + BD Combinations
        • Number of Patients Currently Receiving Darzalex and Empliciti
          • Darzalex and Empliciti Prescribed by High Proportion of Surveyed Physicians One-Year Postlaunch
          • Darzalex and Empliciti Prescription Rate
          • Mean Number of Darzalex- and Empliciti-Treated Patients
          • Darzalex Discontinuation Rate Among Prescribers
          • Reasons for Discontinuing Darzalex Treatment
          • Empliciti Discontinuation Rate Among Prescribers
          • Reasons for Discontinuing Empliciti Treatment
          • Percentage of Patients in Whom Dosages Were Withheld Due to Adverse Events
          • Extent of Admitted Off-Label Prescribing of Darzalex and Empliciti
          • Patient Populations Prescribed Darzalex Off-Label
          • Patient Populations Prescribed Empliciti Off-Label
          • Extent of Prescribing of Darzalex and Empliciti by Line of Therapy
          • Physician-Reported Patient Share by Line of Therapy
          • Impact of the Launch of Darzalex and Empliciti on Prescribing of Other Therapies
          • Mean Impact of the Launch of Darzalex and Empliciti on Prescribing of Other Agents
          • Physician Quotes on Current Use of Darzalex
          • Physician Quotes on Current Use of Empliciti
        • Reasons for Not Yet Prescribing Darzalex and Empliciti
          • Key Reasons for Not Yet Prescribing Darzalex and Empliciti
          • Factors Holding Back Physicians from Prescribing Darzalex in the Fourth-Line
          • Factors Holding Back Physicians from Prescribing Empliciti in the Relapsed/Refractory Setting
          • Physician Quotes on Reasons for Not Prescribing Darzalex and Empliciti
        • Anticipated Darzalex and Empliciti Use
          • Anticipated Future Use of Darzalex and Empliciti by Nonprescribers
          • Potential Displacement of Exisiting Treatments by Darzalex and Empliciti
          • Physician Quotes on Anticipated Darzalex and Empliciti Use
        • Darzalex and Emplicti Performance on Key Attributes
          • Satisfaction Levels for Darzalex and Empliciti Remain High
          • Overall Levels of Satisfcation with Darzalex and Empliciti in Multiple Myeloma
          • Levels of Satisfation with the Efficacy of Darzalex and Empliciti in Multiple Myeloma
          • Levels of Satisfaction with the Safety and Tolerability of Darzalex and Empliciti in Multiple Myeloma
          • Determinants of Treatment Selection
          • Darzalex and Empliciti: Attribute Performance Ratings
          • Darzalex-Based Combinations: Attribute Performance Ratings
          • Darzalex and Empliciti: Comparative Attribute Selections
      • Effectiveness of Face-to-Face Detailing for Darzalex and Empliciti
        • Darzalex and Empliciti Sales Representative Frequency and Reach
          • Slight Increase in Number of Physicians Visited by Darzalex and Empliciti Representatives at One-Year Postlaunch
          • Time of Last Contact with Darzalex and Empliciti Sales Representative
        • Satisfaction with Darzalex and Empliciti Sales Representatives
          • Satisfaction with Darzalex and Empliciti Sales Representatives Is High
          • Sales Representative Performance Rating on Select Major Attributes
          • Average Level of Performance of Sales Representative
        • Darzalex and Empliciti Message Recall
          • Darzalex and Empliciti's Clinical Trial Data, and OS and PFS Data Were the Main Messages Communicated by Sales Representatives
          • Topics Discussed by Sales Representatives
          • Distribution of Patient Education Materials
          • Physician Quotes on Darzalex and Empliciti Message Recall
      • Methodology
        • Primary Market Research Methodology
        • Years in Clinical Practice
        • Practice Type
        • Percentage of Professional Time Spent in Clinical Practice
        • Number of Multiple Myeloma Patients
        • Number of Hematological Oncologists in Practice
        • Practice Location
        • Distribution of Hematological Oncologists by Region
      • Appendix
        • Abbreviations
          • Additional Information
            • Level of Familiarity with Various Drugs for Multiple Myeloma Treatment
            • Average Level of Familiarity with Various Drugs for Multiple Myeloma Treatment
            • Gaps in Awareness About Darzalex and Empliciti Profiles
            • Gaps in Awareness About Darzalex and Empliciti Profiles
            • Reasons for Choosing to Prescribe Other Agents Over Darzalex in the Fourth-Line
            • Reasons for Choosing to Prescribe Other Agents Over Empliciti in the Relapsed/Refractory Setting
            • Patient Inquiries About Darzalex and Empliciti in the Past Month
            • Percentage of Patients with Specific Drug Requests Who Were Started on Darzalex or Empliciti
            • Most Likely Prescription in Various Multiple Myeloma Patient Settings
            • Coordination of Simultaneous Dosings for Patients Prescribed Darzalex or Empliciti to Minimize Drug Waste
            • Reasons for Not Coordinating Darzalex Dosing
            • Reasons for Not Coordinating Empliciti Dosing
            • Managed Care Approval Requirements for Darzalex and Empliciti
            • Influence of Managed Care Approval on Prescribing of Darzalex and Empliciti
            • Ease of Managed Care Approval Process for Darzalex and Empliciti
            • Reasons for Darzalex and Empliciti's Managed Care Approval Process Being Difficult and Time Consuming
            • Insurance Plan Restrictions on Darzalex Treatment Duration
            • Insurance Plan Restrictions on Empliciti Treatment Duration
            • Percentage of Darzalex and Empliciti Prescriptions Denied by MCOs
            • Main Reasons for Darzalex Prescription Denial
            • Main Reasons for Empliciti Prescription Denial
            • Preferred Therapy Choices for Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone
            • Drivers for Starting Case Study Patient #1 on Darzalex
            • Barriers to Starting Case Study Patient #1 on Darzalex
            • Percentage of Physicians That Prescribe Empliciti + Revlimid + Dexamethasone
            • Drivers for Starting Case Study Patient #1 on Empliciti + Revlimid + Dexamethasone
            • Barriers to Starting Case Study Patient #1 on Empliciti + Revlimid + Dexamethasone
            • Change in Therapy Choice if Disease Was Well Controlled for 24 Months in Patient Who Received Revlimid + Dexamethasone First-Line
            • Preferred Therapy Choices for Patient with Multiple Myeloma Previously Prescribed Revlimid + Dexamethasone in First-Line
            • Slight Drop in Darzalex Prescribers Compared with Wave 2 for Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone
            • Increase in Empliciti Prescribers Compared with Wave 2 for Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone
            • Preferred Therapy Choices for Patient with Multiple Myeloma Quickly Progressed to Fourth Line of Therapy
            • Increase in Darzalex Prescribers Compared with Wave 2 for Patient with Multiple Myeloma Quickly Progressed to Fourth-Line Therapy
            • Drivers for Starting Case Study Patient #2 on Darzalex
            • Barriers to Starting Case Study Patient #2 on Darzalex
            • Drivers for Starting Patient on Empliciti + Revlimid + Dexamethasone
            • Barriers for Starting Patient on Empliciti + Revlimid + Dexamethasone
            • Physician Willingness for a Follow-Up Interview About Darzalex and Empliciti

      Author(s): Izabela Ammermann, PhD

      Izabela Ammermann, Ph.D., M.Sc., is a business insights analyst in the oncology division at Decision Resources Group. She is a specialist in multiple myeloma and pancreatic cancer and has expertise in chronic lymphocytic leukemia. Dr. Ammermann holds a Ph.D. in molecular biology from the Technical University of Munich and a M.Sc. in biotechnology from the Polish Academy of Sciences. Prior to joining Decision Resources Group, Dr. Ammermann worked as a postdoctoral research associate (Marie Curie research fellow) at Imperial College London. Dr. Ammermann has published several peer-reviewed papers.


      Related Reports

      Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

      The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

      View Details

      Multiple Myeloma - Epidemiology - Emerging Markets

      DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

      View Details

      Multiple Myeloma - Epidemiology - Mature Markets

      DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

      View Details

      Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

      DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

      View Details